Clinical Trial Update: Study of a Single Intravenous (IV) Dose of MK-3402 in Participants With Impaired Renal Function and in Healthy Controls (MK-3402-004) [Phase 1]

View source ↗

Summary

Phase 1 study of a single IV dose of MK-3402 in participants with renal impairment and healthy controls was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Impairment

Drugs mentioned

• MK-3402

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Renal Impairment | Phase 1 | Status: TERMINATED | Results posted: 2022-11-04